Attana

Attana is a biotechnology startup founded in 2002 and headquartered in Sweden. They specialize in providing the life science community with world-class instruments and services. The company's core focus lies in offering analytical instruments and services for validating, selecting, and optimizing drug candidates. With a track record of analyzing over 75 candidates, Attana has significantly improved the overall clinical trial success rate by more than 4x. By accurately classifying candidates prior to clinical trials, they enable pharmaceutical companies to concentrate on the most promising candidates, thereby enhancing their efficiency and profitability. Attana's vision revolves around in vitro characterization of molecular interactions, mimicking in vivo conditions. They have developed proprietary label-free biosensors for a range of assays, including biochemical, crude, sera, and cell-based tests. Additionally, the company is in the process of developing the Attana Virus Analytics (AVA) platform, a proprietary in vitro diagnostics tool, for applications such as SARS-CoV-2 testing and immunity profiling. Currently, there is no information available regarding the last investment or the investors involved with Attana. To learn more about their latest services and products, interested parties can visit www.attana.com or contact [email protected].